Trump Impact on Medicare Drug Price Negotiations Uncertain
Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.
Funding cuts and regulatory changes could radically reduce Medicaid, the largest program providing medical and health-related ...
The feds intend to appeal a judge's decision that would force them to recalculate UnitedHealthcare's Medicare Advantage (MA) ...
The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by ...
Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with ...
In November, a federal judge ordered CMS to recalculate UnitedHealthcare's Medicare Advantage Star Ratings for the 2025 plan ...
The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...
Federal health agencies, including the Centers for Medicare & Medicaid Services, have halted their communication efforts in ...
Transparency in the program is more than just a mechanism for fair pricing—it is a driving force that diminishes the returns ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback